Analyst Price Targets — JNJ
Latest News for JNJ
JNJ faces Stelara and upcoming drug LOEs, MedTech weakness and talc litigation, but targets accelerated growth in 2026 and beyond.
Johnson & Johnson is rated HOLD for the next 6-12 months, with balanced risk, as its drug portfolio offsets Stelara losses, but MedTech remains a weak growth engine. JNJ's valuation is above historical averages, already pricing in competent execution; further upside requires clear evidence of accelerating growth in both Innovative Medicine and MedTech. Free cash flow and profitability remain strong, but dividends…
Johnson & Johnson (JNJ) closed at $271.19 in the latest trading session, marking a +2.01% move from the prior day.
Replacing nearly $47,000 a year in retirement income without touching principal sounds like a math problem, but the real trap is choosing the wrong yield tier and watching either your paycheck or your nest egg quietly shrink.
Both Johnson and Johnson and Procter & Gamble just refreshed decades-long dividend streaks, but one company has a corporate event on the horizon that has derailed other legendary payout records before.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.